Ji Xia1, Qiang Luo1, Shengbin Huang1, Fuquan Jiang1, Lin Wang2,3, Guanghui Wang1, Jingjing Xie1, Jie Liu1, Yang Xu1. 1. School of Pharmaceutical Sciences, Fujian Provincial Key Laboratory of Innovative Drug Target Research, Xiamen University, Xiamen 361101, China. 2. Department of Oncology, Zhongshan Hospital of Xiamen University, Xiamen 361004, China. 3. Institute of Gastrointestinal Oncology, Medical College of Xiamen University, Xiamen 361101, China.
Abstract
OBJECTIVE: The present study aimed to investigate the molecular events in alisol B 23-acetate (ABA) cytotoxic activity against a liver cancer cell line. METHODS: First, we employed a quantitative proteomics approach based on stable isotope labeling by amino acids in cell culture (SILAC) to identify the different proteins expressed in HepG2 liver cancer cells upon exposure to ABA. Next, bioinformatics analyses through DAVID and STRING on-line tools were used to predict the pathways involved. Finally, we applied functional validation including cell cycle analysis and Western blotting for apoptosis and mTOR pathway-related proteins to confirm the bioinformatics predictions. RESULTS: We identified 330 different proteins with the SILAC-based quantitative proteomics approach. The bioinformatics analysis and the functional validation revealed that the mTOR pathway, ribosome biogenesis, cell cycle, and apoptosis pathways were differentially regulated by ABA. G1 cell cycle arrest, apoptosis and mTOR inhibition were confirmed. CONCLUSIONS: ABA, a potential mTOR inhibitor, induces the disruption of ribosomal biogenesis. It also affects the mTOR-MRP axis to cause G1 cell cycle arrest and finally leads to cancer cell apoptosis.
OBJECTIVE: The present study aimed to investigate the molecular events in alisol B 23-acetate (ABA) cytotoxic activity against a liver cancer cell line. METHODS: First, we employed a quantitative proteomics approach based on stable isotope labeling by amino acids in cell culture (SILAC) to identify the different proteins expressed in HepG2 liver cancer cells upon exposure to ABA. Next, bioinformatics analyses through DAVID and STRING on-line tools were used to predict the pathways involved. Finally, we applied functional validation including cell cycle analysis and Western blotting for apoptosis and mTOR pathway-related proteins to confirm the bioinformatics predictions. RESULTS: We identified 330 different proteins with the SILAC-based quantitative proteomics approach. The bioinformatics analysis and the functional validation revealed that the mTOR pathway, ribosome biogenesis, cell cycle, and apoptosis pathways were differentially regulated by ABA. G1 cell cycle arrest, apoptosis and mTOR inhibition were confirmed. CONCLUSIONS: ABA, a potential mTOR inhibitor, induces the disruption of ribosomal biogenesis. It also affects the mTOR-MRP axis to cause G1 cell cycle arrest and finally leads to cancer cell apoptosis.
Entities:
Keywords:
Alisol B 23-acetate; apoptosis; cell cycle; mTOR; ribosome proteins
Authors: Giovanni Stallone; Antonio Schena; Barbara Infante; Salvatore Di Paolo; Antonella Loverre; Giulio Maggio; Elena Ranieri; Loreto Gesualdo; Francesco Paolo Schena; Giuseppe Grandaliano Journal: N Engl J Med Date: 2005-03-31 Impact factor: 91.245
Authors: Betty Y K Law; Mingfu Wang; Dik-Lung Ma; Fawaz Al-Mousa; Francesco Michelangeli; Suk-Hang Cheng; Margaret H L Ng; Ka-Fai To; Anthony Y F Mok; Rebecca Y Y Ko; Sze Kui Lam; Feng Chen; Chi-Ming Che; Pauline Chiu; Ben C B Ko Journal: Mol Cancer Ther Date: 2010-03-02 Impact factor: 6.261
Authors: Katherine M Hannan; Yves Brandenburger; Anna Jenkins; Kerith Sharkey; Alice Cavanaugh; Lawrence Rothblum; Tom Moss; Gretchen Poortinga; Grant A McArthur; Richard B Pearson; Ross D Hannan Journal: Mol Cell Biol Date: 2003-12 Impact factor: 4.272